secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0000950170-25-069124
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma Q1 net loss $12.3M; announces BI collaboration for CUE-501 and $20M capital raise
--------------------------------------------------------------------------------

- Net loss $12.3M ($0.17 EPS) vs $12.3M ($0.25) YoY; revenue $0.4M down from $1.7M.
- Announced Boehringer Ingelheim collaboration for CUE-501: $12M upfront + up to $345M milestones.
- Raised ~$20M gross in follow-on capital raise; received $12M BI upfront in April 2025.
- Regained worldwide rights to lead autoimmune program CUE-401; virtual event May 15 with KOLs.
- R&D spend $8.5M vs $10.2M YoY; G&A flat at $4.2M; cash $13.1M at Mar 31.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000095017025069124/0000950170-25-069124-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000095017025069124/cue-20250512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-069124

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer